PYC Therapeutics Limited
PYCXF
$0.8462
$0.178626.75%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | 16.44% | 25.28% | 35.76% | 40.73% | 48.06% |
| Total Revenue | 16.44% | 25.28% | 35.76% | 40.73% | 48.06% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 16.44% | 25.28% | 35.76% | 40.73% | 48.06% |
| SG&A Expenses | 16.95% | 13.13% | 7.38% | -14.72% | -30.02% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 73.09% | 63.92% | 51.36% | 29.12% | 7.90% |
| Operating Income | -128.52% | -95.83% | -61.93% | -21.93% | 14.73% |
| Income Before Tax | -124.72% | -92.48% | -59.32% | -20.07% | 15.75% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -124.72% | -92.48% | -59.32% | -20.07% | 15.75% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 2,267.36% | 54.64% | -33.53% | -75.74% | -98.02% |
| Net Income | -122.56% | -92.98% | -61.62% | -23.42% | 12.07% |
| EBIT | -128.52% | -95.83% | -61.93% | -21.93% | 14.73% |
| EBITDA | -130.69% | -97.63% | -63.23% | -22.64% | 14.52% |
| EPS Basic | -82.66% | -55.50% | -30.48% | -3.23% | 22.27% |
| Normalized Basic EPS | -81.12% | -55.93% | -31.53% | -4.95% | 19.94% |
| EPS Diluted | -82.66% | -55.50% | -30.48% | -2.82% | 22.72% |
| Normalized Diluted EPS | -81.12% | -55.93% | -31.53% | -4.95% | 19.94% |
| Average Basic Shares Outstanding | 25.02% | 23.86% | 22.59% | 16.65% | 10.64% |
| Average Diluted Shares Outstanding | 25.02% | 23.86% | 22.59% | 16.65% | 10.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |